mTRP-2 (180-188)
Based on 1 Customer Validation
mTRP-2 (180-188) is an MHC class I-restricted tumor-associated antigenic peptide derived from mouse tyrosinase-related protein 2 (TRP-2). mTRP-2 (180-188) binds to HLA-A*0201 with an ID50 of 36 nM. mTRP-2 (180-188) can be presented by H-2Kb molecules and activate TRP-2-specific cytotoxic T lymphocytes (CTL). mTRP-2 (180-188) induces immune responses against B16 melanoma by promoting antigen-specific T cell proliferation, cytokine release, and CTL-mediated tumor cell killing. mTRP-2 (180-188) can be used in studies related to melanoma, glioma, and tumor immunology.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 219312-69-3
- Formula: C61H78N10O14
- Molecular Weight:1175.33
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[2]|
HLA-A*0201 36 nM (ID50) |
In Vitro
mTRP-2 (180-188) (5 μg/mL) stimulates mouse splenocytes to generate TRP-2-specific CTLs, and the generated CTLs recognize B16 melanoma cells and exert antigen-specific cytotoxic effects[1].
mTRP-2 (180-188) induces the generation of CTLs from HLA-A0201-positive melanoma samples, and these CTLs specifically recognize peptide-loaded T2 cells, COS-7 cells expressing HLA-A0201/TRP-2, as well as HLA-A2-positive and TRP-2-positive melanoma cells[2].
mTRP-2 (180-188) (1 μM; 5 days) stimulates TRP-2-specific TCR transgenic lymphocytes in the presence of IL-2 and generates CD8+ T cell effector cells with potent antigen-specific cytotoxic activity[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Dendritic cell vaccine loaded with mTRP-2 (180-188) induces CTL-mediated protective immune responses in C57BL/6 mice and inhibits the growth of subcutaneous B16 melanoma[3].
mTRP-2 (180-188) (1 μM; 5 days) generates TRP-2-specific CD8+ T cell effector cells in vitro. Repeated intravenous transfer of these cells reduces B16 lung tumor nodules, but does not significantly inhibit the growth of subcutaneous B16 tumors[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (H-2b) (male, 8-12 weeks of age, melanoma model via s.c. challenge with 1×105 live B16F10 melanoma cells)[3]
-
Dosage:mTRP-2 (180-188): 25 μM for DC loading; DCs: 4 × 105
-
Administration:s.c.; twice with 2-week interval
-
Result:Induced high-avidity TRP-2-specific CTLs and provided approximately 80% protection against subsequent B16 melanoma challenge.
-
Animal Model:C57BL/6 (female, 6-12 weeks old, intravenous injection of 2×105 B16/BL6 melanoma cells to induce pulmonary tumor nodules)[5]
-
Dosage:mTRP-2 (180-188): 1 μM during ex vivo T-cell activation; TRP-2-specific effector cells: 1 × 107/mouse
-
Administration:i.v.; 3 doses on days 3, 7, 11 after tumor challenge
-
Result:Significantly reduced the number of pulmonary B16 tumor nodules compared to control groups.
Significantly reduced lung weight compared to control groups.
-
Animal Model:C57BL/6 (female, 6-12 weeks old, subcutaneous injection of 1×105 B16/BL6 melanoma cells)[5]
-
Dosage:5×106 TRP-2(180-188)-specific TCR transgenic lymph node cells; 2.5×105 TRP-2(180-188)-pulsed bone marrow-derived dendritic cells per dorsal flank
-
Administration:i.v. (lymph node cells); s.c. (dendritic cells)
-
Result:Did not reduce subcutaneous B16 tumor growth compared to control-vaccinated or untransferred mice.
Maintained high CD44 expression, granzyme B expression, and IFN-γ production with only modest, statistically significant reductions in IFN-γ at later time points.
Maintained high CD107a mobilization with only modest, statistically significant reductions in CD107a at later time points.
-
Animal Model:C57BL/6 (female, 6-12 weeks old, intravenous injection of 2×105 B16/BL6 melanoma cells to induce pulmonary tumor nodules)[5]
-
Dosage:5×106 TRP-2(180-188)-specific TCR transgenic lymph node cells; 2.5×105 TRP-2(180-188)-pulsed bone marrow-derived dendritic cells per dorsal flank
-
Administration:i.v. (lymph node cells); s.c. (dendritic cells; 3 days after tumor challenge)
-
Result:Did not reduce the number of pulmonary B16 tumor nodules compared to control groups.
Chemical Information
-
CAS No. 219312-69-3
-
Appearance Solid
-
Molecular Weight 1175.33
-
Formula C61H78N10O14
-
Color White to off-white
-
Sequence
Ser-Val-Tyr-Asp-Phe-Phe-Val-Trp-Leu
-
Sequence Shortening
SVYDFFVWL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Solvent & Solubility
In Vitro:
DMSO : ≥ 50 mg/mL (42.54 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhu X, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Journal of translational medicine. 2007 Feb 12;5:10. [Content Brief]
[2]. Parkhurst MR, et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer research. 1998 Nov 01;58(21):4895-901. [Content Brief]
[3]. Schreurs MWJ, et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 2000;60:6995-7001. [Content Brief]
[4]. Singh V, et al. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009;32(2):129-39. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8508 mL | 4.2541 mL | 8.5082 mL | 21.2706 mL |
| 5 mM | 0.1702 mL | 0.8508 mL | 1.7016 mL | 4.2541 mL | |
| 10 mM | 0.0851 mL | 0.4254 mL | 0.8508 mL | 2.1271 mL | |
| 15 mM | 0.0567 mL | 0.2836 mL | 0.5672 mL | 1.4180 mL | |
| 20 mM | 0.0425 mL | 0.2127 mL | 0.4254 mL | 1.0635 mL | |
| 25 mM | 0.0340 mL | 0.1702 mL | 0.3403 mL | 0.8508 mL | |
| 30 mM | 0.0284 mL | 0.1418 mL | 0.2836 mL | 0.7090 mL | |
| 40 mM | 0.0213 mL | 0.1064 mL | 0.2127 mL | 0.5318 mL |
mTRP-2 (180-188) Related Classifications
HY-P1827 Related Classifications
Powered by Bioz